Advances in the treatment of cutaneous lupus erythematosus
Advances in the treatment of cutaneous lupus erythematosus
复制标题
DOI：
10.1177/0961203316641771
复制
发表时间：
2016-07-01
期刊：
影响因子：
2.6
通讯作者：
Wenzel, J.
中科院分区：
文献类型：
--
作者：
Kuhn, A.;Landmann, A.;Wenzel, J.
红斑狼疮（LE）是一种多因素自身免疫性疾病，其临床表现严重程度不同，皮肤表现可作为疾病的主要体征（皮肤红斑狼疮，CLE）或作为疾病谱的一部分（系统性红斑狼疮，SLE）。到目前为止，还没有药物被批准专门用于治疗CLE，只有单一药物已被应用于随机对照试验。因此，局部和全身药物是超说明书使用的，主要基于开放标签研究、病例系列、回顾性分析和专家意见。相反，几种药物，如羟氯喹、氯喹、环磷酰胺、硫唑嘌呤和贝利木单抗，被批准用于治疗SLE。最近的方法在理解LE的分子发病机制，使进一步的新的药物，其目标分子，如白细胞介素6（IL-6）和干扰素（IFN）的发展。然而，只有单一试验将这些新药物应用于皮肤受累的患者和/或包括评价这些药物对皮肤表现的疗效的终点。本文就CLE治疗的新方法和最新进展作一综述。
Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used off-label, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine, and belimumab, are approved for the treatment of SLE. Recent approaches in the understanding of the molecular pathogenesis of LE enabled the development of further new agents, which target molecules such as interleukin 6 (IL-6) and interferon (IFN). Only single trials, however, applied these new agents in patients with cutaneous involvement of the disease and/or included endpoints which evaluated the efficacy of these agents on skin manifestations. This article provides an updated review on new and recent approaches in the treatment of CLE.